Kornimate/medical-research-clean huggingface dataset:
study of psychopathological characteristics of patient smoking in thoracic oncology

Conditions: Smoking Cessation and Lung Cancer

Summary: persistent smoking after lung cancer has been the subject of medical, therapeutic and epidemiological publications for twenty years of research. continued persistent smoking is all the more a problem for oncologists as there is evidence that smoking cessation, with lung cancer, gives therapeutic benefit. quitting smoking can improve the response to treatments (chemotherapy, radiotherapy, surgery), quality of life and overall survival. however many patients refuse adhesion to tobacco cessation. daily practice leads us to the hypothesis that adhesion differences aren't related to the denial of medical information, nor to resignation or to nicotine dependence. patients who continue smoking seem to face a form of impossibility to wean. cigarette seems to be felt as a part of their body in their narration and description of their body image.


Eligibility criteria:
inclusion criteria: * men and women aged 18 years or older * patient affiliated to a social security system * patient who has signed and dated informed consent, written before all procedures related to the study * patient who has received the results of the previous mandatory medical examination * patient who has been diagnosed with lung cancer, regardless of the histological type of the cancer * patient who maintains an active smoking at the time of inclusion * patient who has smoked at least one cigarette in the previous year of inclusion * patient who is being treated for lung cancer (surgery, chemotherapy, radiotherapy) and not another form of cancer * tobacco consumer's only by smoke inhalation * tobacco consumer's or tobacco associated with cannabis exclusion criteria: * major patient under guardianship or curatorship or maintenance of justice * patient deprived of his liberty or in an emergency situation * patient with a performance statut(oms) higher than 2 and/or with a psychiatric disorder like " schizophrenia and other psychotic disorders " (dsm iv) * a palliative care patient * patient who began smoking during his diagnostic examination or after the diagnosis of cancer * a pregnant or breastfeeding woman * patient in an exclusion period
double lumen tube intubation

Conditions: Endotracheal Intubation; Cardiac Arrest

Summary: the aim of this study was to compare time, success rates of different double-lumen tubes in intubation in a standardized manikin model.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * minimum 1 year of work experience in emergency medicine * experienced emergency medicine personnel (physicians, nurses, paramedics) exclusion criteria: * not meet the above criteria * wrist or low back diseases
t-lymphocyte infusion or standard therapy in treating patients at risk of cytomegalovirus infection after a donor stem cell transplant

Conditions: Graft Versus Host Disease; Nonneoplastic Condition

Summary: rationale: an infusion of cytomegalovirus-specific t lymphocytes may prevent or reduce cytomegalovirus infection during the first year after a donor stem cell transplant. purpose: this randomized phase ii trial is studying t-lymphocyte infusion to see how well it works compared with standard therapy in treating patients at risk of cytomegalovirus infection after a donor stem cell transplant.

objectives: primary * to determine the frequency of cytomegalovirus (cmv) reactivation during the first year after allogeneic stem cell transplantation (asct) in patients at risk for cmv infection treated with adoptive transfer of selected cmv-specific cytotoxic t-lymphocytes. secondary * to monitor cmv-specific immune reconstitution within the first year following asct in these patients. * to determine the time to cmv reactivation in these patients. * to evaluate the use of antiviral therapy in these patients. * to determine the incidence of secondary cmv reactivation and cmv disease in patients treated with this regimen. * to determine the incidence of acute and chronic graft-versus-host disease. outline: this is a multicenter study. after undergoing an allogeneic peripheral blood stem cell transplantation (pbsct) using an alemtuzumab-based conditioning regimen that also includes radiotherapy, patients are randomized to 1 of 2 treatment arms. * arm i: patients receive cytomegalovirus (cmv)-specific cytotoxic t-lymphocyte infusion on day 21-90 after allogeneic pbsct. * arm ii: patients undergo standard follow-up care and receive standard antiviral therapy comprising ganciclovir iv or foscarnet sodium upon detection or confirmation of cmv reactivation. blood samples are collected to assess cmv viral load by quantitative pcr. after completion of study therapy, patients are followed once a week for 100 days and then once a month for 1 year. projected accrual: a total of 18 patients with sibling donors and 21 patients with unrelated donors are accrued for each arm, resulting in a total of 78 patients accrued for this study.

Eligibility criteria:
disease characteristics: * planning allogeneic peripheral blood stem cell transplantation (pbsct) using a conditioning regimen containing alemtuzumab and radiotherapy * sibling or matched unrelated donor available * patients and donor matched for ≥ one of the following hla alleles: * hla-a\*0101 * hla\*0201 * hla-a\*1101 * hla-a\*2402 * hla-b\*0702 * hla-b\*0801 * hla-b\*3502 * no donors whose stem cells have already been collected and cryopreserved prior to transplant * patient and donor must be cmv seropositive * stem cell harvests ≥ 4.0 x 10\^6 cd34 cells/kg patient characteristics: * see disease characteristics prior concurrent therapy: * see disease characteristics * no prior bone marrow transplantation * no concurrent participation in another therapeutic transplantation study

Keywords: cytomegalovirus infection graft versus host disease
letrozole vs clomiphene citrate for induction of ovulation in women with polycystic ovarian syndrome

Conditions: Polycystic Ovary Syndrome; Infertility

Summary: it was randomised controlled study to compare the efficacy of clomiphene and letrozole in polycystic ovarian syndrome(pcos) women with infertility.the aim was to select more appropriate treatment for ovulation induction in pcos women.

the prevalence of infertility due to polycystic ovarian syndrome in pakistan is 21.9%.it leads to an ovulation which results in infertility.the objective of this study was to compare the efficacy of letrozole vs clomiphene citrate for ovulation induction in pcos women.methods.it was a randomised controlled trial conducted in department of gynaecology and obstetrics ,services hospital lahore from 2016-2019. total 230 patients were included in study, they were divided in two groups, out of which 220 patients were analysed. .group-a patients were given clomiphene citrate 50-150mg per day for 5 days starting from 2nd day of menses and group b patients were given letrozole 2.5-7.5mg per day for 5 days. transvaginal ultrasound monitoring done from day 10-12 of menstrual cycle to measure follicle number and size.when follicle achieved a diameter of 18-20mm, then inj hcg(human chorionic gonadotropin)10,000 iu intramuscular was given. ovulation was confirmed by day 21 s.progesterone. when patient conceived, they were followed up till delivery.

Eligibility criteria:
inclusion criteria: * women age between 18-40 years. * normal husband semen analysis. exclusion criteria: * all infertile couples who had other causes of infertility than pcos. * those who had recently taken these medications. * any contraindication to use of drugs e.g renal or hepatic dysfunction, hypersensitivity to this drug. * bmi\>35 because obese women respond poorly to ovulation induction.

Keywords: polycystic ovary syndrome infertility clomiphene citrate letrozole
role of non-contrast mdct in the assessment of upper urinary tract calculi post eswl to predict its success rate

Conditions: Urinary Stone

Summary: urinary stones are a common disease affecting one in 11 people . their clinical presentation varies from being silent to severe loin pain owing to urinary obstruction. currently, eswl is the treatment of choice for most renal calculi ⩽30 mm, with success rates of 60-99%. although many treatment options exist, eswl has the advantages of simplicity and non-invasiveness. in contrast, failure of a first eswl attempt requires a follow-up eswl procedure, or an alternative procedure, both of which increase medical costs. advancements in imaging have significantly contributed to this process. in the mid- 1990s, computed tomography (ct) began to replace intravenous urography (ivu), abdominal films (kub), and ultrasound (us) in stone diagnosis. studies demonstrated that ct had superior sensitivity and specificity for stone diagnosis compared to the aforementioned modalities. now non-contrast multidetector ct (nc-mdct) is the gold standard for the detection of urinary system calculi. ct is also clinically useful as it can show alternate renal and non-renal pathology if present. many factors have been reported to predict eswl outcome, such as skin-to-stone distance (ssd), stone size, stone location, multiplicity, the energy used, and hounsfield unit (hu) values measured by non-contrast computed tomography (ncct).

excellent fragmentation results are produced using eswl. however, the retention of post-eswl fragments in the kidney continues to be a significant medical issue. only 32% of calcium stone patients in research were found to remain stone-free for 12 months following eswl, according to the results. as a result, it appears that fragment growth and persistence are frequent after eswl \[10\]. the first eswl residual that is accessible must undergo a thorough stone analysis to properly carry out the subsequent treatments to prevent relapse or recurrent stone because stone-free rates after eswl are directly connected to stone placement, size, number, and composition

Eligibility criteria:
inclusion criteria: * patients older than 18 years. * stone size up to 25 mm for renal pelvic stones and up to 15 mm for upper ureteric stones. * ssd \< 11 cm. exclusion criteria: * any patient with contraindications to eswl as * uncontrolled urinary infection. * clotting alterations. * aortic or renal artery aneurysm. * pregnancy. * serious skeletal malformations. * serious obesity and or contraindications to ct as pregnancy.
study to evaluate the exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction

Conditions: Substance Withdrawal Syndrome; Opiate Addiction; Opiate Dependence

Summary: the purpose of this study is to evaluate the relative exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction.

this is a phase 1, open-label, inpatient study in male and female subjects seeking at least a 4 mg reduction of their buprenorphine maintenance dose. the purpose of this study is to assess the relative exposures of lofexidine and its 3 major metabolites in subjects tapering from buprenorphine maintenance treatment. lofexidine is an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids.

Eligibility criteria:
inclusion criteria: * have current dependency such that the subject is maintained on a daily dose between 8 and 24 mg of buprenorphine and is seeking reduction of their buprenorphine dose by at least 4 mg. * urine toxicology screen positive for buprenorphine at screening. * agree to collection of blood samples for genotyping of cyp2d6 metabolizer status. * if female and of childbearing potential, subject must have been using birth control for at least 30 days and must agree to use an acceptable form of birth control through at least 30 days after the last dose of study drug. * if male, must agree to use an acceptable form of birth control throughout the entire study period and for 90 days after the last dose of study drug. must not donate sperm for 90 days after the last dose of study drug. exclusion criteria: * be a female subject who is pregnant or lactating. * have a very serious medical illness not under control. * have participated in an investigational drug study within the past 30 days. * received any drugs that are known strong, moderate or weak inhibitors of cytochrome p450 (cyp) enzymes cyp1a2, cyp2c19, or cyp2d6, within 14 days or 5 half-lives (whichever is more) before day -1. * abnormal cardiovascular exam at screening. * subjects requiring the following will be excluded: tricyclic antidepressants, which may reduce the efficacy of imidazoline derivatives; beta-receptor blockers, to avoid the risk of excessive bradycardia.

Keywords: substance withdrawal syndrome opiate addiction opiate dependence opioid withdrawal syndrome buprenorphine
intranasal ketamine for pain control in patients with sickle cell disease and vaso-occlusive episode (voe) in the ped

Conditions: Sickle Cell Disease; Vaso-Occlusive Pain Episode in Sickle Cell Disease; Vaso-occlusive Crisis; Ketamine; Intranasal Ketamine; Analgesia

Summary: this will be a descriptive cohort study of intranasal ketamine as the initial analgesic for children with sickle cell disease who present to the pediatric emergency department with vaso-occlusive crisis and are awaiting intravenous line placement.

this will be a prospective observational cohort involving patients 3 to 25 years of age who present to the pediatric emergency department (ped) at jacobi medical center with vaso-occlusive episode (voe) in moderate-severe pain (faces or numeric rating scale ≥5) as determined at triage. currently, the standard of treatment for voe at our institution is intravenous (iv) line placement and iv opioid analgesia. the patient will receive intranasal (in) ketamine as the first parental analgesic, so as to provide more immediate pain relief while they wait for iv placement and iv analgesia, for opioid pain control, which is currently the standard of care at our institution. the primary objective of this study is to describe the analgesic effect of in ketamine in treating moderate-to-severe pain due to voe in the pediatric ed as measured by a pain scale rating at various time intervals following administration. secondary objectives are to describe the effect of in ketamine on the need for additional doses of opioid medications, patient satisfaction and disposition.

Eligibility criteria:
inclusion criteria: * history of hemoglobin ss or sc disease * age 3 years old to 25 years old presenting to the ped with vaso-occlusive with moderate-severe pain determined at triage as pain score (faces or numeric rating scale) ≥ 5 * parent or patient willing to provide consent/assent * english speaking exclusion criteria: * patient with concern for more severe complications including acute chest, splenic sequestration, sepsis, stroke, non-voc pain, asthma exacerbation * allergy to ketamine * gcs\<15 * obstructive nasal anatomy as per parent history * history of a psychiatric disorder * pregnant patients will be excluded. female patients \> 12 years old are routinely tested for pregnancy in our ped. patients found to be pregnant will not be enrolled in study.
capnography during percutaneous transhepatic cholangiodrainage (ptcd) (hepabreath)

Conditions: Apnea; Hypoxemia; Complications

Summary: capnography provides noninvasive monitoring of ventilation and can allow early recognition of altered respiration patterns and apnea. the aim of this prospective study was to compare the detection of apnea and the prediction of oxygen desaturation and hypoxemia by capnography versus clinical surveillance during procedural sedation for percutaneous transhepatic cholangiodrainage (ptcd).


Eligibility criteria:
inclusion criteria: * age\>=18 * scheduled for ptcd with midazolam and propofol sedation exclusion criteria: * age less than 18 years * asa class v * allergy to narcotic drugs * pregnancy * pre-existing hypotension, bradycardia or hypoxemia
siemens voc tb pilot study

Conditions: Tuberculosis

Summary: tuberculosis is a bacterial infection causing 1.1 million deaths annually worldwide. diagnosis of the disease is often time consuming or challenging. many cases of tuberculosis require advanced and expensive diagnostic methods that restrict their availability in resource limited countries where the burden of tuberculosis is highest. the development of rapid point of care diagnostics is required. published data confirm that trained african giant-pouched rats are able to identify m. tuberculosis cultures through olfactory recognition. a first trial using an electronic nose reported a rate of detection of 85% in tuberculosis patients. a further trial was closed in june 2011 but remains unpublished, yet. the olfactory pattern that potentially allows the recognition of tuberculosis remains unknown. this trial aims to detect first patterns of volatile organic compounds (vocs) that bear a potential for further development and fine tuning. a technical prototypic device of siemens is used for pattern detection. the study is comparing 3 groups of patients: * patients with confirmed active pulmonary tuberculosis (n=20) * patients with other inflammatory lung diseases (pneumonia, sarcoidosis, copd, bronchial carcinoma) (n=20) * healthy volunteers that do not work in the hospital or visit the hospital regularly detailed data for all study subjects will be collected for this trial in order to eliminate confounding factors. furthermore, detailed data of the surroundings of the patient, the surroundings of the technical device and of the operator will be captured. hypothesis: the pattern of exhaled volatile organic compounds allows the detection of pulmonary tuberculosis


Eligibility criteria:
inclusion criteria: 1. confirmed pulmonary infection with m. tuberculosis (mtb) or other inflammatory disease of the lower respiratory tract (i.e. pneumonia, sarcoid, bronchial carcinoma) or healthy subject that is not employed or working at the study site 2. oral and written consent to study participation exclusion criteria: 1. tuberculosis therapy \>1 week 2. inability to follow the study requirements 3. patient in custodianship or guardianship 4. other lung diseases that are not listed in the inclusion criteria.

Keywords: tuberculosis volatile organic compounds exhaled breath siemens
continuous infusion of remidazolam for colonoscopic polypectomy in elderly patients

Conditions: Colon Disease

Summary: to observe the sedative effect of continuous infusion of remidazolam in elderly patients undergoing colonoscopic polypectomy.

to observe the sedative effect of continuous infusion of remidazolam in elderly patients undergoing colonoscopic polypectomy, and to screen the optimal dose of remidazolam, in order to provide a more reasonable and safe sedative and analgesic drug regimen for elderly outpatients undergoing colonoscopic polypectomy.

Eligibility criteria:
inclusion criteria: * age 60-80 years old; * asa level i - iii; * operation time: 15min\~1h; * bmi18.0-29.9； exclusion criteria: * emergency surgery; * patients with high risk of gastric satiety and reflux aspiration; * allergies to benzodiazepines and opioids; * those who have taken sedative, analgesic, or antidepressant drugs within 24 hours; * abnormal liver and kidney function; * previous drug use history; * recently participated in other clinical studies; * patients who cannot cooperate with communication.

Keywords: colonoscopic polypectomy elderly patients
outpatient management of patients with exacerbation of chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: patients admitted to the hospital with chronic obstructive pulmonary disease are evaluated with regard to early follow-up by a specialized nurse in the home after discharge.

patients admitted to department of internal medicine m, glostrup university hospital, with chronic obstructive pulmonary disease (copd) are evaluated with regard to early follow-up by a specialized nurse in the home after discharge. eligible patients receive education about disease management. the intervention is evaluated by comparing the number of readmissions for copd and the duration of admissions during the study period to the the period prior to the implementation of this intervention.

Eligibility criteria:
inclusion criteria: * admission for chronic obstructive pulmonary disease exclusion criteria: * other severe acute or chronic diseases

Keywords: chronic obstructive pulmonary disease outpatient management nurse-lead patient education
scapholunate ligament partial tears; tear localization, extrinsic ligament injury association and conservative treatment responses prior to instability

Conditions: Scapholunate Ligament Partial Tears

Summary: the purpose of this study is to investigate scapholunate ligament partial tears regarding tear localization, extrinsic ligament accompaniment in stable wrist and accordingly to scrutinize conservative treatment response.

patients admitted with radial sided wrist pain without carpal instability were retrospectively evaluated. scapholunate interosseous ligament (sliol) tear localization, grade of injury and associated extrinsic ligament injuries were examined on mri. patients treated conservatively and recalled at their first year for re-evaluation.

Eligibility criteria:
inclusion criteria: * scapholunate ligament injury * wrist extrinsic ligament injury exclusion criteria: * scapholunate dissociation * radiological and clinical instable wrist * carpal bone fracture * mri imaging artefact

Keywords: scapholunate interosseous ligament, extrinsic wrist ligaments, carpal instability, mri of wrist, wrist ligamentous injury,